1. Plasma amyloid beta, neurofilament light chain, and total tau in the Systolic Blood Pressure Intervention Trial (SPRINT)
- Author
-
Manjula Kurella Tamura, Alfred K. Cheung, Joachim H. Ix, Jason D Hinman, Jeff D. Williamson, Clinton B. Wright, Lenore J. Launer, Donna M. Wilcock, Ilya M. Nasrallah, Tiffany L. Sudduth, Nicholas M. Pajewski, Alan J. Lerner, Lindsay M Miller, David M. Reboussin, Fanny M. Elahi, Anthony A. Killeen, and Mark A. Supiano
- Subjects
medicine.medical_specialty ,Epidemiology ,Amyloid beta ,Intermediate Filaments ,Renal function ,Blood Pressure ,tau Proteins ,Cellular and Molecular Neuroscience ,Developmental Neuroscience ,Alzheimer Disease ,Internal medicine ,medicine ,Humans ,Dementia ,Cognitive Dysfunction ,Intervention trial ,Amyloid beta-Peptides ,biology ,business.industry ,Health Policy ,Standard treatment ,Neurodegeneration ,medicine.disease ,Psychiatry and Mental health ,Blood pressure ,Sprint ,biology.protein ,Cardiology ,Neurology (clinical) ,Geriatrics and Gerontology ,business ,Biomarkers - Abstract
INTRODUCTION Lowering blood pressure (BP) reduces the risk for cognitive impairment and the progression of cerebral white matter lesions. It is unclear whether hypertension control also influences plasma biomarkers related to Alzheimer's disease and non-disease-specific neurodegeneration. METHODS We examined the effect of intensive (
- Published
- 2021